Clinical cancer advances 2015: Annual report on progress against cancer from the American society of clinical oncology

Journal of Clinical Oncology

Volumn 33, Issue 7, 2015, Pages 786-809

  Masters, Gregory A ^a   Krilov, Lada ^b   Bailey, Howard H ^c   Brose, Marcia S ^d   Burstein, Harold ^e   Diller, Lisa R ^e   Dizon, Don S ^f   Fine, Howard A ^g   Kalemkerian, Gregory P ⁱ   Moasser, Mark ^k   Neuss, Michael N ⁿ   O'Day, Steven J ^m   Odenike, Olatoyosi ^o   Ryan, Charles J ^l   Schilsky, Richard L ^b   Schwartz, Gary K ^h   Venook, Alan P ^l   Wong, Sandra L ^j   Patel, Jyoti D ^p  

^a HELEN F GRAHAM CANCER CENTER   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c University of Wisconsin Health   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m Peninsula Beverly Hills   (United States)

ⁿ VANDERBILT INGRAM CANCER CENTER   (United States)

^o UNIVERSITY OF CHICAGO   (United States)

^p NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AZD9291; BEVACIZUMAB; CANCER VACCINE; CERITINIB; CHLORAMBUCIL; DULOXETINE; DURVALUMAB; EMACTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IBRUTINIB; IDELALISIB; IPILIMUMAB; LAPATINIB; LENVATINIB; NEW DRUG; NIVOLUMAB; OBINUTUZUMAB; OFATUMUMAB; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PERTUZUMAB; PLX3397; RAMUCIRUMAB; ROCILETINIB; TISAGENLECLEUCEL T; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; AGE; BLOOD EXAMINATION; BRAIN CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CANCER SCREENING; CANCER STEM CELL; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; CONFERENCE PAPER; DRUG APPROVAL; DRUG TARGETING; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENOME ANALYSIS; GENOMICS; GLIOMA; HEALTH; HEALTH CARE ACCESS; HUMAN; INTESTINE FLORA; LEUKEMIA; LEUKEMIA RELAPSE; LUNG CANCER; MEDICAL SOCIETY; MELANOMA; MENOPAUSE; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NANOMEDICINE; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PATIENT CARE; PERIPHERAL NEUROPATHY; PIGMENTED VILLONODULAR SYNOVITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH CANCER; T LYMPHOCYTE; THYROID CANCER; TIME TO TREATMENT; TUMOR IMMUNITY; UNITED STATES; UTERINE CERVIX CANCER; ADVERSE EFFECTS; BREAST NEOPLASMS; COMPLICATION; EARLY DIAGNOSIS; FEMALE; FINANCIAL MANAGEMENT; GENETICS; GOVERNMENT; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLISM; NEOPLASMS; OBESITY; ONCOLOGY; PROSTATIC NEOPLASMS; RARE DISEASE; TRENDS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CANCER VACCINES; DRUG APPROVAL; EARLY DETECTION OF CANCER; FEDERAL GOVERNMENT; FEMALE; FINANCING, GOVERNMENT; GENOMICS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; OBESITY; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RARE DISEASES; RESEARCH SUPPORT AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84925234844     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.9746     Document Type: Conference Paper

References (55)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
2. US Food and Drug Administration: FDA approves Gazyva for chronic lymphocytic leukemia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373209.htm
3. Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014
4. US Food and Drug Administration: Ofatumumab. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm393823.htm
5. US Food and Drug Administration: FDA approves Imbruvica to treat chronic lymphocytic leukemia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm385764.htm
6. Byrd JC, Brown JR, O'Brien S, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014
7. US Food and Drug Administration: FDA expands approved use of Imbruvica for chronic lymphocytic leukemia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406916.htm
8. US Food and Drug Administration: FDA approves Zydelig for three types of blood cancers. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm406387.htm
9. National Cancer Institute: Obesity and cancer risk. http://www.cancer.gov/cancertopics/factsheet/Risk/obesity
10. Cuzick J, Sestak I, Forbes JF, et al: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): An international, double-blind, randomised placebo-controlled trial. Lancet 383:1041-1048, 2014
11. Moyer VA: Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160:330-338, 2014
12. Kovalchik SA, Tammemagi M, Berg CD, et al: Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 369:245-254, 2013
13. de Koning HJ, Meza R, Plevritis SK, et al: Benefits and harms of computed tomography lung cancer screening strategies: A comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 160:311-320, 2014
14. Sozzi G, Boeri M, Rossi M, et al: Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: A correlative MILD trial study. J Clin Oncol 32:768-773, 2014
15. Tammemägi MC, Berg CD, Riley TL, et al: Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst 106:dju084, 2014
16. Buckner JC, Pugh SL, Shaw EG, et al: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in lowgrade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32, 2014 (suppl 15s; abstr 2000)
17. Sweeney C, Chen Y-H, Carducci MA, et al: Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormonesensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32, 2014 (suppl 15s; abstr LBA2)
18. Janne PA, Ramalingam SS, Yang JC-H, et al: Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. J Clin Oncol 32, 2014 (suppl 15s; abstr 8009)
19. Sequist LV, Soria J-C, Gadgeel SM, et al: First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 32, 2014 (suppl 15s; abstr 8010)
20. US Food and Drug Administration: Ceritinib. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm395386.htm
21. Shaw AT, Kim DW, Mehra R, et al: Ceritinib in ALK-rearranged non-small cell lung cancer. N Engl J Med 370:1189-1197, 2014
22. US Food and Drug Administration: FDA approves Cyramza for stomach cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394107.htm
23. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39, 2014
24. Schlumberger M, Tahara M, Wirth LJ, et al: A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 32, 2014 (suppl 15s; abstr LBA6008)
25. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol 32, 2014 (suppl 15s; abstr LBA9008)
26. Rizvi NA, Garon EB, Patnaik A, et al: Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer. J Clin Oncol 32, 2014 (suppl 15s; abstr 8007)
27. Garon EB, Leighl NB, Rizvi NA, et al: Safety and clinical activity of MK-3475 in previously treated patients with non-small cell lung cancer. J Clin Oncol 32, 2014 (suppl 15s; abstr 8020)
28. Gettinger SN, Shepherd FA, Antonia SJ, et al: First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 32, 2014 (suppl 15s; abstr 8024)
29. Brahmer JR, Rizvi NA, Lutzky J, et al: Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol 32, 2014 (suppl 15s; abstr 8021)
30. Davila ML, Riviere I, Wang X, et al: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25, 2014
31. Grupp SA, Frey NV, Aplenc R, et al: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without Gvhd in children and adults with relapsed, refractory ALL. Blood 122, 2013 (abstr 67)
32. Tap WD, Anthony SP, Chmielowski B, et al: A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS). J Clin Oncol 32, 2014 (suppl 15s; abstr 10503)
33. Cassier PA, Gomez-Roca CA, Italiano A, et al: Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS). J Clin Oncol 32, 2014 (suppl 15s; abstr 10504)
34. Brown J, Brady WE, Schink J, et al: Efficacy and safety of bevacizumab in recurrent sex cordstromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 120:344-351, 2014
35. Zimmerman C, Swami N, Krzyanowsla M, et al: Early palliative care for patients with advanced cancer: A cluster-randomized controlled trial. Lancet 383:1721-1730, 2014
36. Moore HCF, Unger JM, Phillips K-A, et al: Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in earlystage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol 32, 2014 (suppl 15s; abstr LBA505)
37. Lambertini M, Boni L, Michelotti A, et al: Long-term outcome results of the phase III Promise-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients. J Clin Oncol 32, 2014 (suppl; abstr 105)
38. American Society of Clinical Oncology: The state of cancer care in America, 2014: A report by the American Society of Clinical Oncology. J Oncol Pract 10:119-142, 2014
39. Levit L, Balogh E, Nass S, et al: (eds): Delivering High-Quality Care: Charting a New Course for a System in Crisis. Washington, DC, National Academies Press, 2013
40. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 500:415-421, 2013
41. Hoadley KA, Yau C, Wolf DM, et al: Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158:929-944, 2014
42. Antonarakis ES, Lu C, Hao W, et al: Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 32, 2014 (suppl 15s; abstr 5001)
43. Iida N, Dzutsev A, Stewart CA, et al: Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342:967-970, 2013
44. Viaud S, Saccheri F, Mignot G, et al: The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342: 971-976, 2013
45. Chen X, Stewart E, Shelat AA, et al: Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24:710-724, 2013
46. Buczkowicz P, Hoeman C, Rakopoulos P, et al: Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46:451-456, 2014
47. Taylor KR, Mackay A, Truffaux N, et al: Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46:457-461, 2014
48. Jelinic P, Mueller JJ, Olvera N: Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet 46:424-426, 2014
49. Witkowski L, Carrot-Zhang J, Albrecht S, et al: Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 46:438-443, 2014
50. Ramos P, Karnezis AN, Craig DW, et al: Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet 46:427-429, 2014
51. US Food and Drug Administration: FDA approves Keytruda for advanced melanoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm
52. Temel JS, Greer JA, Muzikansky A, et al: Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733-742, 2010
53. Smith TJ, Temin S, Alesi ER, et al: American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care. J Clin Oncol 30:880-887, 2012
54. Katki HA, Kinney WK, Fetterman B, et al: Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice at a large managed care organization. Lancet Oncol 12:663-672, 2011
55. Shastri SS, Mittra I, Mishra G, et al: Effect of visual inspection with acetic acid (VIA) screening by primary health workers on cervical cancer mortality: A cluster randomized controlled trial in Mumbai, India. J Clin Oncol 31, 2013 (suppl 15s; abstr 2)